Harlé A, Gavoille C, Bouché O, Abdelghani MB, Plaza J, Spaeth D, Boudrant A, Ghiringhelli F, Villing AL, Borg C, Rouyer M, Husson M, Gilson P, Salleron J, Lambert A, Merlin JL

Oncol Lett. 2026 01;31(1):13

Radiotherapy in the management of PDAC, from past to present.

Dardare J, Martz N, Witz A, Betz M, Michel C, Gilson P, Merlin JL, Lambert A, Harle A

Transl Oncol. 2025 12 8;63:102632

Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies.

Dardare J, Martz N, Witz A, Betz M, Michel C, Gilson P, Merlin JL, Lambert A, Harle A

Int J Radiat Oncol Biol Phys. 2025 09 16;:

A novel ddPCR assay for BRCA1 and RAD51C methylation: Advancing HRD Detection in Ovarian Cancer.

Michel C, Simon A, Witz A, Hanriot I, Dardare J, Betz M, Brun M, Gilson P, Merlin JL, Harlé A

J Mol Diagn. 2025 08 7;:

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.

Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P, Merlin JL, Harlé A

Biomark Res. 2025 02 21;13(1):31

Decoding mutational signatures in breast cancer: Insights from a multi-cohort study.

Betz M, Witz A, Dardare J, Michel C, Massard V, Boidot R, Gilson P, Merlin JL, Harlé A

Transl Oncol. 2025 02 4;53:102315

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib.

Dardare J, Witz A, Betz M, François A, Lamy L, Husson M, Demange J, Rouyer M, Lambert A, Merlin JL, Gilson P, Harlé A

Cell Death Discov. 2024 09 27;10(1):411

Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?

Witz A, Dardare J, Betz M, Gilson P, Merlin JL, Harlé A

Clin Exp Med. 2024 01 17;24(1):2

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.

Pozzorini C, Andre G, Coletta T, Buisson A, Bieler J, Ferrer L, Kempfer R, Saintigny P, Harlé A, Vacirca D, Barberis M, Gilson P, Roma C, Saitta A, Smith E, Consales Barras F, Ripol L, Fritzsche M, Marques AC, Alkodsi A, Marin R, Normanno N, Grimm C, Müllauer L, Harter P, Pignata S, Gonzalez-Martin A, Denison U, Fujiwara K, Vergote I, Colombo N, Willig A, Pujade-Lauraine E, Just PA, Ray-Coquard I, Xu Z

Cell Rep Med. 2023 12 19;4(12):101344

Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS).

Merlin JL, Husson M, Sahki N, Gilson P, Massard V, Harlé A, Leroux A

Biomedicines. 2023 11 28;11(12):

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.

Witz A, Dardare J, Francois A, Husson M, Rouyer M, Demange J, Merlin JL, Gilson P, Harlé A

Sci Rep. 2023 10 31;13(1):18741

Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

Betz M, Massard V, Gilson P, Witz A, Dardare J, Harlé A, Merlin JL

Cancers (Basel). 2023 10 27;15(21):

Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers.

Gilson P, Pouget C, Belmonte R, Fadil S, Demange J, Rouyer M, Lacour J, Betz M, Dardare J, Witz A, Merlin JL, Harlé A

Sci Rep. 2023 08 9;13(1):12909

DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.

Dardare J, Witz A, Betz M, Francois A, Meras M, Lamy L, Lambert A, Grandemange S, Husson M, Rouyer M, Demange J, Merlin JL, Harlé A, Gilson P

Front Oncol. 2022 12 8;12:1052163

Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.

Gilson P, Merlin JL, Harlé A

Cancers (Basel). 2022 Mar 8;14(6):

Intraoperative prediction of non-sentinel lymph node metastases in breast cancer using cytokeratin 19 mRNA copy number: A retrospective analysis.

Pina H, Salleron J, Gilson P, Husson M, Rouyer M, Leroux A, Rauch P, Marchal F, Käppeli M, Merlin JL, Harlé A

Mol Clin Oncol. 2022 Mar;16(3):58

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities.

Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harlé A

Pharmaceuticals (Basel). 2021 Jul 29;14(8):

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.

Gilson P, Saurel C, Salleron J, Husson M, Demange J, Merlin JL, Harlé A

Sci Rep. 2021 May 18;11(1):10470

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA).

Gilson P, Merlin JL, Harlé A

Cancers (Basel). 2021 Mar 24;13(7):

Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers.

Gilson P, Levy J, Rouyer M, Demange J, Husson M, Bonnet C, Salleron J, Leroux A, Merlin JL, Harlé A

. 2020 Oct 2;10(1):16386

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.

Dardare J, Witz A, Merlin JL, Gilson P, Harlé A

Int J Mol Sci. 2020 May 16;21(10):

Enrichment and Analysis of ctDNA.

Gilson P

Recent Results Cancer Res.. 2020 ;215:181-211

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.

Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, Gambier N, Scala-Bertola J, Merlin JL, Harlé A

PLoS ONE. 2020 ;15(1):e0227294

Rapid fully-automated assay for routine molecular diagnosis of mutations for personalized therapy of low grade gliomas.

Merlin MS, Gilson P, Rouyer M, Chastagner P, Doz F, Varlet P, Leroux A, Gauchotte G, Merlin JL

Pediatr Hematol Oncol. 2019 Oct 23;:1-12

Emerging Roles of DDB2 in Cancer.

Gilson P, Drouot G, Witz A, Merlin JL, Becuwe P, Harlé A

Int J Mol Sci. 2019 Oct 18;20(20):

Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing.

Franczak C, Kandathil SM, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A

Sci Rep. 2019 May 8;9(1):7083

The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.

Gilson P, Couvet M, Vanwonterghem L, Henry M, Vollaire J, Baulin V, Werner M, Orlowska A, Josserand V, Mahuteau-Betzer F, Lafanechère L, Coll JL, Busser B, Hurbin A.

Biochem Pharmacol.. 2019 Feb;160:1-13

Technical considerations for circulating tumor DNA detection in oncology.

Franczak C, Filhine-Tresarrieu P, Gilson P, Merlin JL, Au L, Harlé A

Expert Rev. Mol. Diagn.. 2019 Jan 16;:

Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.

Gilson P, Franczak C, Dubouis L, Husson M, Rouyer M, Demange J, Perceau M, Leroux A, Merlin JL, Harlé A

PLoS ONE. 2019 ;14(7):e0219204

Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.

Franczak C, Dubouis L, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A

PLoS ONE. 2019 ;14(2):e0212801

Clinical Interests of Circulating Tumor DNA in Oncology.

Franczak C, Filhine-Tressarieu P, Broséus J, Gilson P, Merlin JL, Harlé A

Arch. Med. Res.. 2018 Nov 7;:

Accelerated mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma.

Serre D, Salleron J, Husson M, Leroux A, Gilson P, Merlin JL, Geoffrois L, Harlé A

Oncotarget. 2018 Aug 14;9(63):32232-32237

Evaluation and validation of HPV real-time PCR assay for the detection of HPV DNA in oral cytobrush and FFPE samples.

Harlé A, Guillet J, Thomas J, Sastre-Garau X, Rouyer M, Ramacci C, Gilson P, Dubois C, Dolivet G, Leroux A, Salleron J, Merlin JL

Sci Rep. 2018 Jul 27;8(1):11313

Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.

Gilson P, Josa-Prado F, Beauvineau C, Naud-Martin D, Vanwonterghem L, Mahuteau-Betzer F, Moreno A, Falson P, Lafanechère L, Frachet V, Coll JL, Fernando Díaz J, Hurbin A, Busser B

Sci Rep. 2017 Aug 31;7(1):10209

Fiche personne Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques